UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 8-K/A
(Amendment No. 1)
CURRENT REPORT
Pursuant to Section 13 or 15(d)
of the
Securities Exchange Act of 1934
Date of report (Date of earliest event reported): October 12, 2021
Inspyr Therapeutics, Inc.
(Exact name of registrant as specified in Charter)
| Delaware | 0001421204 000-55331 | 20-0438951 | ||
(State or other jurisdiction of | (Commission File No.) | (IRS Employee Identification No.) |
2629 Townsgate Road, Suite 215
Westlake Village CA 91361
(Address of Principal Executive Offices)
818-661-6302
(Issuer Telephone number)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Securities registered pursuant to Section 12(b) of the Act:
| Title of Class | Trading Symbol | Name of Each Exchange on Which Registered | ||
| N/A | N/A | N/A |
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (17 CFR §230.405) or Rule 12b-2 of the Securities Exchange Act of 1934 (17 CFR §240.12b-2). Emerging growth company ☐
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
EXPLANATORY NOTE
On October 12, 2021, Inspyr Therapeutics Inc.. (the “Company”) filed with the Securities and Exchange Commission a Current Report on Form 8-K (the “Initial 8-K”) to report the 1-for-75 reverse stock split and holding company reorganization. This Form 8-K/A amends the Initial 8-K to disclose the correct date that the Company will begin trading under the symbol RBSH to twenty (20) trading days from the date hereof.
| Item 8.01 | Other Events. |
On October 12, 2021, Inspyr Therapeutics, Inc., (the “Company”), announced the completion of (i) the 1-for-75 reverse stock split as previously disclosed, and (ii) its reorganization into a holding company structure changing its corporate name. At the market open on October 12, 2021, the Company will begin trading on a post-split basis as Rebus Holdings, Inc. and twenty (20) trading days thereafter, it will begin trading under the new symbol RBSH. The new CUSIP is 75619J 103.
1
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this Report on Form 8-K to be signed on its behalf by the undersigned hereunto duly authorized.
Dated: October 12, 2021
| Inspyr Therapeutics, Inc. | ||
| By: | /s/ Raul Silvestre | |
| Raul Silvestre Chief Executive Officer | ||
2
